Immune Checkpoint Inhibitors versus VEGF Targeted Therapy as Second Line Regimen in Advanced Hepatocellular Carcinoma (HCC): A Retrospective Study

Immune Checkpoint Inhibitors versus VEGF Targeted Therapy as Second Line Regimen in Advanced Hepatocellular Carcinoma (HCC): A Retrospective Study

Several targeted agents including multi-tyrosine kinase inhibitors (mTKIs) and immunotherapy (IO) agents have been approved for use beyond the frontline setting in patients with advanced hepatocellular carcinoma (HCC). Due to lack of prospective head-to-head comparative trials, there is no standardi...

Full description

Bibliographic Details
Main Authors: Anwaar Saeed, Hannah Hildebrand, Robin Park, Mohammed Al-Jumayli, Saqib Abbasi, Tina Melancon, Azhar Saeed, Raed Al-Rajabi, Anup Kasi, Joaquina Baranda, Stephen Williamson, Weijing Sun
Format: Article
Language:English
Published: MDPI AG 2020-08-01
Series:Journal of Clinical Medicine
Subjects:
hepatocellular carcinoma
immunotherapy
checkpoint inhibitors
Program Death Ligand 1
targeted therapy
multi-tyrosine kinase inhibitors
Online Access:https://www.mdpi.com/2077-0383/9/9/2682

Internet

https://www.mdpi.com/2077-0383/9/9/2682

Similar Items